Australia's most trusted
source of pharma news
Posted 22 January 2026 AM
Striking new data shows that Moderna's cancer vaccine in combination with MSD's Keytruda continued to halve the death rate for patients with resected high-risk melanoma, even after five years.
The companies announced "sustained improvement" in the primary endpoint of recurrence-free survival from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study evaluating intismeran autogene (mRNA-4157 or V940), an investigational mRNA-based individualised neoantigen therapy, in combination with Keytruda in patients with stage III/IV melanoma following resection.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.